Recce Pharmaceuticals Ltd.

As of June 30, 2026, Recce Pharmaceuticals Ltd. carries a market capitalization of 117.12M, placing it among publicly traded companies globally. Its enterprise value stands at 124.87M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Recce Pharmaceuticals Ltd.'s next confirmed earnings release is scheduled for March 1, 2027.

As of June 30, 2026, Recce Pharmaceuticals Ltd. has 289.18M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Recce Pharmaceuticals Ltd. maintains a current ratio of 0.44, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -62.44, indicating conservative leverage, while an interest coverage ratio of -14.24 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -142.88, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Recce Pharmaceuticals Ltd.'s stock has declined approximately 13.75% over the past 52 weeks. The 50-day moving average sits at 0.34, while the 200-day moving average is 0.46.

These figures cover the twelve months ended June 30, 2026. EBITDA reached -22.81M, while operating income came in at -23.16M.

As of June 30, 2026, Recce Pharmaceuticals Ltd. holds 2.69M in cash and equivalents against 10.44M in total debt, resulting in a net debt position of 7.08M. Total book value stands at -16.72M, with working capital of -9.21M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -1.72, meaning Recce Pharmaceuticals Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Recce Pharmaceuticals Ltd.'s most recent stock split took place on April 15, 2025 with a 104:105 split ratio.